Decision Infrastructure

The decision layer that makes
Phase II defensible.

Certified, audit-trailed recommendations for clinical development teams making go/no-go calls.
We foster innovation from concept through commercialization.

Book a Conversation How It Works

The Problem

Phase II is where
biopharma value
is won or lost.

28%
of drug programs successfully complete Phase II. The rest fail — at a cost measured in years and hundreds of millions.
90%
of Phase II trials experience at least one substantial protocol amendment. The average is 3.3 amendments per trial.
~$2.1M
in direct cost per amendment, plus 3 months of unplanned delay — before accounting for opportunity cost and investor impact.

Most failures aren't surprises in hindsight. The signals were available. The intelligence wasn't governed.

01
Decisions Go Undocumented
Go/no-go calls are made verbally, on whiteboards, in slide decks that disappear. When regulators, acquirers, or boards ask what was known and when — there's no answer.
02
Data Is Fragmented
Biological, clinical, payer, and regulatory signals live in separate systems with no integration layer. The cross-signal insight that predicts failure doesn't exist until it's too late.
03
No Institutional Memory
Every program repeats the same patterns from failed predecessors. Without a governed record that connects predictions to outcomes, lessons cannot accumulate.

Our Solution

Intelligent decision
infrastructure for
regulated biopharma.

Governed Data Integration
Biological, clinical, payer, and regulatory data integrated through a governed architecture with documented attribution at every step.
Multi-Dimensional Risk Assessment
Phase II success probability, FDA approval likelihood, payer feasibility, and commercial viability — evaluated together, not in silos.
Human Review, Always
Every recommendation is reviewed and approved by a qualified professional before delivery. Accountability is built in, not optional.
Auditable Decision Records
Every recommendation is linked to the decision it informed — creating a searchable, inspection-ready record that survives due diligence.

Offerings

Three ways Foster Rx
creates value.

Core Platform
Phase II Decision Intelligence

Certified decision support for biopharma teams at pre- and mid-Phase II. Covers the four risk dimensions that determine whether an asset is worth advancing — with a governed evidence bundle every time.

  • Phase 2 Trial Success Probability
  • FDA Approval Probability
  • Payer Feasibility Score
  • Commercial Outcome Predictor
  • Inspection Readiness Package
Data Products
Curated Healthcare AI Datasets

Statistically faithful, privacy-preserving synthetic datasets derived from certified real-world sources. Built for pharma AI teams who need representative training data without downstream license exposure.

  • AI-Ready Synthetic RWD
  • Synthetic Control Arms for rare disease
  • White-label partner product available
  • Full SYNTHETIC_DATA certificate chain
Discovery & Transfer
Translational Viability & Tech Transfer

For academic groups and early-stage programs, Foster Rx evaluates translational viability and produces a structured Asset Intelligence Data Room — ready for BD engagement, licensing, or investor due diligence.

  • Orphan drug target identification
  • Asset Intelligence Data Room
  • Two AI-discovered assets available now
  • Fee-for-service & co-development models
Core System Patent Pending · No. 19/459,855
200+ KOLs Engaged
2 AI-Discovered Orphan Assets

The Team

Built by someone who has
lived the problem.

Gabrielle Foster
Gabrielle Foster
Founder & Chief Executive

Former Takeda R&D Clinical Operations leader. MIT-trained data scientist. Doctoral researcher in AI-enabled clinical trials. Gabrielle has designed research protocols, led regulatory inspection readiness programs, and managed clinical studies across global development programs. Foster Rx was built to solve the governance problems she observed firsthand at the intersection of clinical operations and AI adoption in biopharma.

MIT, Johns Hopkins, Takeda, Gates Foundation, Harvard, Maveric
ORCID LinkedIn Google Scholar

Work With Us

Built for the scientists and teams
who refuse to guess.

Whether you're a pharma team navigating go/no-go, a biotech preparing for a board, a CRO building for sponsors, or an academic researcher bridging the bench-to-trial gap — if your decisions need to be defensible, Foster Rx was built for you.

Book a Conversation